- $37.09m
- $17.20m
- $12.29m
Brief: Elutia Inc Received Nasdaq Letter Stating Co No Longer In Compliance With Board Independence Rule
Brief: Elutia Inc - Files Prospectus For Offering Up To 18.6 Million Shares Of Class A Common Stock By Selling Securityholders
To Purchase Elutia's Orthobiologics Business For $15 Million In Advance, With Additional Royalties Of Up To $20 Million Over Next 5 Years
Brief: Elutia Announces Sale Of Orthobiologics Business Unit For Cash Proceeds Of Up To $35 Million
Brief: Aziyo Biologics Q2 revenue USD 10.296 million
Aziyo Biologics Inc reports results for the quarter ended in June - Earnings Summary
Aziyo Biologics Inc expected to post a loss of 29 cents a share - Earnings Preview
Aziyo Biologics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Aziyo Biologics Reports First Quarter Results
Aziyo Biologics Inc expected to post a loss of 54 cents a share - Earnings Preview
Aziyo up on distribution pact with LeMaitre for cardiovascular portfolio
Brief: Lemaitre To Distribute Aziyo Biologics’ Cardiovascular Patches
U.S. STOCKS ON THE MOVE-Manchester United, Verona Pharma, 89Bio
U.S. STOCKS ON THE MOVE-Ollie, Commercial Metals, Copper Aluminum miners
U.S. STOCKS ON THE MOVE-U.S. banks, Regeneron, Gold miners
Aziyo Biologics gains on higher revenue, smaller loss
Aziyo Biologics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aziyo Biologics Posts Q4 Loss Of $0.38 Per Share
Brief: Aziyo Biologics Inc - Co, Sientra Entered Into Agreement To Expand Distribution Of Aziyo's Simpliderm Product Line